Other languages Scilex Holding Company

Equities

SCLX

US80880W1062

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-06 EDT			5-day change	1st Jan Change
0.8655 ^USD	+0.64%		-6.14%	-57.57%

04-16	Scilex Issues Preliminary Q1 Sales Results for ZTlido	MT
03-20	Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scilex Issues Preliminary Q1 Sales Results for ZTlido	04-16
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label	03-20
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	03-20
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed	03-20
Scilex Holding Company Provides Responses to Product Composition Questions Related to Its ELYXYB® Patent in Canada	03-18
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	03-15
Scilex Holding Company Reports Earnings Results for the Full Year Ended December 31, 2023	03-12
Top Midday Decliners	03-01
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	03-01
US Futures Remain Flat as Investors Await Raft of Economic Data	03-01
Scilex Holding Signs Underwriting Agreement for $10 Million Bought Deal Offering	03-01
Scilex Files $500 Million Mixed-Securities Shelf	01-09
Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023	01-02
Scilex Files New Drug Submission for Migraine Treatment Approval in Canada	12-26
Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada	12-26
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal A High Degree of Interest in Gloperba as Liquid Colchicine Formulation Designed for Precision Dosing	12-19
Scilex Says US Pharmacy Chain to Stock Elyxyb	12-15
Scilex Holding Company Announces Major Pharmacy Initiative with the National Leading Pharmacy Chain to Stock ELYXYB® in Most of Their Stores Throughout the U.S	12-15
Scilex Holding Company Announces Expanded Access to Elyxyb® by the Execution of First Elyxyb® Insurance Coverage Agreement with One of the Top Three National Pbms (Pharmacy Benefit Manager) for Its Medicare Population	12-12
Scilex Holding Company Announces ZTlido Will Be Added as a Preferred Agent to the Medicaid Preferred Drug List in Two New States: One Midwestern and One Southern State	12-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Scilex Holding Company

Equities

SCLX

US80880W1062

Other languages

Filters